Supporting the best innovations to address the global threat of AMR
We can protect more patients worldwide if we tackle the growing threat of antimicrobial resistance. PACE is a £30 million initiative that will focus on early-stage antimicrobial drug and diagnostics projects. It will help our best innovators move their research forward with greater speed and confidence. Through the right funding, partnerships, and expertise, we will give their ideas every chance of succeeding and build a world-leading, pre-clinical AMR pipeline that can save lives.
Managing partners with a vision to connect the AMR community
Number of estimated deaths from AMR each year by 2050, if no action is taken
Worth of investment in PACE to tackle AMR
Bringing PACE to AMR research
PACE is a pioneering partnership that will drive the development of new tests and treatments to tackle deadly antimicrobial resistance. It will provide funding and empower scientists and researchers at the early stages of the AMR asset development journey, so they can make a lasting contribution to patient health.
Initiatives aimed at funding and supporting promising research and development to tackle AMR are having significant impact, but we believe PACE will bring a much needed approach and injection of funding and support for a new era of innovation in early-stage translation.
PACE gives us the best chance of making bigger strides towards tackling AMR so we can protect people’s lives across the world. Find out more about PACE.
About PACE
Working with us
If you are an innovator in AMR, then we can increase the pace of your research and make sure it has the best chance of succeeding. PACE will bring together the right funding, resources, and partnerships to help progress early-stage antimicrobial drug and diagnostics projects that address the world’s most threatening pathogens. Learn more about how we can help you.
Apply for Funding
Our Managing Partners
Professor Dame Sally Davies
UK Special Envoy on Antimicrobial Resistance